Pfizer Vs Jnj Stock

last updated on

Pfizer Vs Jnj Stock

Pfizer Vs. Johnson & Johnson: Which Stock Is Better?

Most of the large tech companies are struggling this year. That's why a lot of investors are now trying to reevaluate their portfolios to lower the exposure to the tech sector.

One particular sector that is now getting attention is healthcare. In this sector, the two big names are Pfizer (PFE) and Johnson & Johnson (JNJ).

Pfizer's COVID-19 Vaccine Sales Are Shrinking

JNJ split its business in 2023 and moved the consumer health division under a new brand, Kenvue. It appears that the separation was a good thing, as the revenue jumped from $88.8 billion in 2024 to around $94.2 billion in 2025.

On the other hand, Pfizer is also a big name in the healthcare sector. However, it appears that the sales of Pfizer's COVID-19 vaccine are now declining, which has also affected the total revenue.

In 2022, Pfizer's sales were $100 billion, which went down to $59.5 billion in 2023. In short, it was a big shock for Pfizer, but that was expected as the sales of such vaccines don't generate revenue for too long.

But Pfizer is working on many new drugs and is also acquiring other companies in the healthcare sector. One particular area Pfizer is focusing on is oncology, and they have also acquired Seagen because of that.

For the year 2026, forecasts show that Pfizer's revenue will be $59.5 billion - $62.5 billion. The forward P/E of Pfizer is also 9.6, which shows Pfizer stock is undervalued. On the other hand, the forward P/E of JNJ is 21.1, which is a lot higher than Pfizer!

While Pfizer is struggling and has drugs in the pipeline, JNJ is a different story. Analysts think that JNJ is in a very good position to generate higher earnings in the future.

Also, JNJ has been paying its dividend for 60 years in a row. What's more impressive is that JNJ also continues to raise its dividend yield every year!

When we compare both of these stocks, it becomes clear that JNJ is the better choice. It has a steady cash flow, a broad portfolio, and a history of reliable dividend payouts.

Trending Stories